PlatinumRx: Financial Breakdown
Decoding financial health metrics of PlatinumRx
Total Revenue₹10.7 Cr7843%Prev. FY
Total Expenses₹17.8 Cr2416%Prev. FY
Profit After Tax₹-7.3 Cr-1617%Prev. FY
Total Assets₹12.3 Cr99%Prev. FY
Net Profit Margin-68.2%78%Prev. FY
FAQs on Financials of PlatinumRx
No. In FY25, PlatinumRx reported a net loss of ₹7.3 Cr, so it was not profitable.
PlatinumRx's revenue grew 7843.7% year-on-year, from ₹13.4 Lakh in FY24 to ₹10.7 Cr in FY25.
PlatinumRx's estimated EBITDA for FY25 was ₹-7.1 Cr, derived from its profit before tax, finance costs, and depreciation & amortisation.
In FY25, PlatinumRx posted revenue of ₹10.7 Cr (up 7843.7% YoY) and a net loss of ₹7.3 Cr. Explore the full financials of PlatinumRx here...
Disclaimer
Inc42 Datalabs consolidates intelligence from public records, statutory filings, proprietary research, and vetted third‑party datasets. All information is provided as is—please run your own checks before acting on it. Inc42 Datalabs bears no responsibility for decisions or outcomes based on this data.
Quick Links